The US Supreme Court on Monday rejected a series of appeals from several of the nation’s largest drugmakers challenging a program that is expected to save taxpayers and the federal government billions of dollars by requiring the companies to negotiate with Medicare on the prices for some of their most popular drugs.

The Supreme Court has rejected appeals from pharmaceutical companies that object to negotiating Medicare drug prices with the federal government.

Pharmaceutical companies are trying to prevent Medicare from negotiating discounts for drugs. Their legal challenges have been unsuccessful.